PM: PMI Reaffirms 2026 EPS Growth (11.1%-13.1%)

Philip Morris’ reaffirmation of 2026 adjusted EPS growth of 11.1%–13.1% signals management confidence that core growth drivers from 2025 will continue into 2026. Because reported diluted EPS for 2025 is listed as N/A in the provided summary, the guidance is directional—expressed as a percentage increase on an adjusted basis rather than an absolute per-share target. Key investor takeaways: the company is relying on continued pricing power in cigarettes (supported by leading brands) alongside accelerating scale in smoke-free products (IQOS HTU, ZYN oral pouches, VEEV e-vapor). With SFPs at 22.8% of shipment volume in 2025 and double-digit volume growth in HTU (+11.0% YoY) and oral SFPs (+18.5% YoY), the reaffirmed range reflects expectations that these mix improvements and margin expansion persist in 2026.

Smoke-free product momentum: SFPs represented 179.1 billion equivalent units (22.8% of total 786.5 billion) in 2025. HTU (IQOS platform) and oral products (ZYN) are the primary contributors, with HTU at 155.1B units (19.7% of total) and oral SFPs rising 18.5% YoY in 2025. Portfolio and geographic positioning: Cigarettes remained the largest category in 2025 at 607.4B units (77.2% of shipments), but SFP mix gains are reshaping revenue composition. Management has moved to a two-unit operating structure (International/U.S.) effective Jan 1, 2026 to sharpen focus on regional execution—an operational change intended to accelerate SFP scaling and capitalize on local market dynamics. Margin and cash-flow support: 2025 gross profit of $27,282M and operating income of $14,892M provide a base for adjusted EPS growth, while the company’s pricing power for leading brands (e.g., Marlboro prominence in Europe) and manufacturing optimization initiatives are the expected margin levers for 2026.

Balance sheet context: 2025 long-term debt stands at $45,134M and total assets are approximately $100,000M (inferred). Stockholders' deficit was $(8,028)M in 2025. These metrics frame the company’s leverage and capital-allocation flexibility as it invests behind the smoke-free transformation. Legal and regulatory risks: The reaffirmation must be viewed against several material risks disclosed for 2024–2025, including multiple U.S. ZYN-related lawsuits (no accruals noted), a proposed Canada tobacco claim (CAD 32.5B proposed settlement with PMI having a 23% RBH stake and a $2.3B impairment in 2024), excise and tax challenges (e.g., Germany TEREA classification assessment), and ongoing regulatory pathways for IQOS (FDA MRTP and EU TPD notifications). These contingencies could affect realized adjusted EPS depending on outcomes. Macro sensitivity: Currency volatility (notably Argentine peso and Egyptian pound impact in 2025), inflation and higher interest rates are cited as potential headwinds given the company’s sizable debt load. Execution is critical—management’s strategy has historically relied more on operational execution than structural moat protection.